Xenetic Biosciences Inc (XBIO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Xenetic Biosciences Inc stock (XBIO) is currently trading at $2.99. Xenetic Biosciences Inc PS ratio (Price-to-Sales) is 2.30. Analyst consensus price target for XBIO is $40.00. WallStSmart rates XBIO as Sell.
- XBIO PE ratio analysis and historical PE chart
- XBIO PS ratio (Price-to-Sales) history and trend
- XBIO intrinsic value — DCF, Graham Number, EPV models
- XBIO stock price prediction 2025 2026 2027 2028 2029 2030
- XBIO fair value vs current price
- XBIO insider transactions and insider buying
- Is XBIO undervalued or overvalued?
- Xenetic Biosciences Inc financial analysis — revenue, earnings, cash flow
- XBIO Piotroski F-Score and Altman Z-Score
- XBIO analyst price target and Smart Rating
Xenetic Biosciences Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Xenetic Biosciences Inc (XBIO) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Xenetic Biosciences Inc (XBIO) Key Strengths (1)
Trading below book value, meaning the market prices it less than net assets
Supporting Valuation Data
Xenetic Biosciences Inc (XBIO) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very low institutional interest at 10.28%
Micro-cap company with very limited liquidity and high volatility
Revenue is fairly priced at 2.30x sales
Solid revenue growth at 18.10% per year
Xenetic Biosciences Inc (XBIO) Detailed Analysis Report
Overall Assessment
This company scores 30/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 1 register as strengths (avg 10.0/10) while 7 fall into concern territory (avg 2.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (0.99) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (2.30) suggest expensive pricing. Growth concerns include Revenue Growth at 18.10%, which may limit upside. Profitability pressure is visible in Return on Equity at -40.00%, Operating Margin at -81.30%, Profit Margin at -90.10%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -40.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 18.10% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
XBIO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
XBIO's Price-to-Sales ratio of 2.30x trades at a deep discount to its historical average of 12.84x (53th percentile). The current valuation is 99% below its historical high of 190.63x set in Jan 2020, and 996% above its historical low of 0.21x in May 2019. Over the past 12 months, the PS ratio has compressed from ~2.9x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Xenetic Biosciences Inc (XBIO) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Xenetic Biosciences Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 3M with 18% growth year-over-year. The company is currently unprofitable, posting a -90.1% profit margin.
Key Findings
Spending 26% of revenue (773,416) on R&D, reinforcing its commitment to innovation and future growth.
The company is unprofitable with a -90.1% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -242,682, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 2.32, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Xenetic Biosciences Inc.
Bottom Line
Xenetic Biosciences Inc offers an attractive blend of growth (18% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(8 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 8:27:59 AM
About Xenetic Biosciences Inc(XBIO)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Xenetic Biosciences, Inc., a biopharmaceutical company, is focused on advancing XCART, a customized chimeric antigen receptor T (CAR T) platform technology designed to target patient-specific tumor neoantigens. The company is headquartered in Framingham, Massachusetts.